A Phase 1 interventional study of Baricitinib and Rifampicin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to look at what effect multiple doses of rifampicin have on a single dose of baricitinib and to look at the safety and tolerability of these drugs. Side effects will be documented. The study will last approximately 31 days from the first dose to the end of the study.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 10 milligrams (mg) baricitinib on Day 1.
Drug: Baricitinib
Oral doses of 600 mg rifampicin once daily on Days 3 to 11, with a single oral dose of 10 mg baricitinib co-administered on Day 10.
Drug: Baricitinib · Drug: Rifampicin
Administered orally
Also known as: LY3009104
Administered orally
PK: Maximum Concentration (Cmax) of Baricitinib
Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
PK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib
Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Time frame: Period 1, Day 1 and Period 2, Day 10: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, and 48 hours postdose
| Milestone | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| Started | 18 |
| Received baricitinib | 18 |
| Completed | 18 |
| Not completed | 0 |
| Milestone | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| Started | 18 |
| Received baricitinib | 18 |
| Received at least 1 dose of rifampicin | 18 |
| Completed | 18 |
| Not completed | 0 |
| nanograms per milliliter (ng/mL) | Baricitinib | Baricitinib and Rifampicin |
|---|---|---|
| PK: Maximum Concentration (Cmax) of Baricitinib | 96.1 ± 22 | 101 ± 28 |
| nanograms*hour/milliliter (ng*h/mL) | Baricitinib | Baricitinib and Rifampicin |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From 0 to Infinity [AUC(0-∞)] of Baricitinib | 634 ± 19 | 416 ± 20 |
| hours (h) | Baricitinib | Baricitinib and Rifampicin |
|---|---|---|
| PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib | 1.00 (0.50 to 2.00) | 1.00 (0.50 to 1.00) |
Collected over Baseline through study completion (up to Day 32). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baricitinib | — | 0/18 (0%) | 3/18 (16.7%) |
| Rifampicin | — | 0/18 (0%) | 3/18 (16.7%) |
| Baricitinib and Rifampicin | — | 0/18 (0%) | 5/18 (27.8%) |
| Event | Baricitinib | Rifampicin | Baricitinib and Rifampicin |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/18 | 0/18 | 2/18 |
| NasopharyngitisInfections and infestations | 1/18 | 0/18 | 2/18 |
| Abdominal pain upperGastrointestinal disorders | 0/18 | 0/18 | 1/18 |
| FlatulenceGastrointestinal disorders | 0/18 | 0/18 | 1/18 |
| Gingival bleedingGastrointestinal disorders | 0/18 | 1/18 | 0/18 |
| VomitingGastrointestinal disorders | 0/18 | 0/18 | 1/18 |
| Chest discomfortGeneral disorders | 1/18 | 0/18 | 0/18 |
| FatigueGeneral disorders | 0/18 | 1/18 | 0/18 |
| ThirstGeneral disorders | 0/18 | 1/18 | 0/18 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 1/18 | 0/18 |
All enrolled participants.
| Age, Continuous(years) | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| Mean | 40.9 ± 15.4 |
| Sex: Female, Male(Participants) | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| Female | 3 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 16 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Baricitinib Then Baricitinib and Rifampicin |
|---|---|
| United Kingdom | 18 |
The record gives a start of Aug 2013, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib